105
Participants
Start Date
October 31, 2011
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
PF-05212384
PF-05212384 intravenous infusion weekly starting at 110 mg.
PD-0325901
PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
PF-05212384
PF-05212384 intravenous infusion weekly starting at 95 mg.
irinotecan
Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
Ospedale San Raffaele, Milan
MUSC Specialty Care-North, North Charleston
Medical University of South Carolina, Hollings Cancer Center, Charleston
Medical University of South Carolina, Charleston
MUSC, Investigational Drug Services, Charleston
MUSC Health East Cooper, Mt. Pleasant
Anschutz Cancer Pavilion, Aurora
University of Colorado Denver (CTRC), Aurora
University of Colorado Hospital Anschutz Inpatient Pavilion, Aurora
University of Colorado Hospital, Aurora
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Medical Center, Los Angeles
UCLA Oncology Center, Los Angeles
Santa Monica - UCLA Medical Center and Orthopaedic Hospital, Santa Monica
UCLA Santa Monica Hematology Oncology, Santa Monica
Ronald Reagan UCLA Medical Center, Los Angeles
Princess Margaret Hospital, Toronto
Hospital General Vall d'Hebron, Barcelona
Lead Sponsor
Pfizer
INDUSTRY